glaucoma 1, open angle, K

Summary

glaucoma 1, open angle, K (MONDO:0012102) is a disease. A subtype of juvenile open angle glaucoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	glaucoma 1, open angle, K
Mondo ID	MONDO:0012102
MeSH	C563873
OMIM	608696
UMLS	C1837527
MedGen	324817
GARD	0018229
Is cancer (heuristic)	no

Also known as: glaucoma 1, open angle, K · glaucoma 1K, primary open angle, juvenile-onset · GLC1K · JOAG1K

Disease family

This is a subtype of juvenile open angle glaucoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › glaucoma › open-angle glaucoma › juvenile open angle glaucoma › glaucoma 1, open angle, K

Related subtypes (5): glaucoma 1, open angle, A, glaucoma 1, open angle, J, glaucoma 1, open angle, M, glaucoma 1, open angle, N, glaucoma 1, open angle, l

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.